NextCure Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon and welcome to day two of the Annual Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Michael Richman, CEO of NextCure. (Conference Instructions) And with that, Mike, the stage is yours.
Great. Well, thank you so much, Gil. It's a real pleasure to be here, and I'd like to thank your team at Needham for the opportunity to present NextCure today.
So hopefully everyone can see my slides. NextCure started a little over six years ago with a vision towards developing next-generation immuno medicines. On this next slide, these are our forward-looking statements. Let me jump to slide 3 which outlines NextCure's highlights.
We call this slide our three Ps. It focuses on our pipeline, our product strategy, and our people. I will be walking through our pipeline
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
